Effects of six second generation antipsychotics on body weight and metabolism risk assessment and results from a prospective study

Pharmacopsychiatry

Volumn 42, Issue 1, 2009, Pages 29-34

  Tschoner, A ^a   Engl, J ^a   Rettenbacher, M ^a   Edlinger, M ^a   Kaser, S ^a   Tatarczyk, T ^a   Effenberger, M ^a   Patsch, J R ^a   Fleischhacker, W W ^a   Ebenbichler, C F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; C REACTIVE PROTEIN; CHOLESTEROL; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; GLUCOSE HOMEOSTASIS; HIGH RISK PATIENT; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC REGULATION; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ADOLESCENT; AGED; BODY WEIGHT; CLINICAL TRIAL; CLUSTER ANALYSIS; DRUG EFFECT; ENZYME IMMUNOASSAY; GLUCOSE BLOOD LEVEL; INTERNATIONAL CLASSIFICATION OF DISEASES; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY WEIGHT; CLUSTER ANALYSIS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERNATIONAL CLASSIFICATION OF DISEASES; LIPID METABOLISM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 64749083959     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1100425     Document Type: Article

References (58)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 ; 15 : 539-553
2. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001 ; 62 : 22-31
3. Allison DB, Mackell JA, MacDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003 ; 54 : 565-567
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 ; 27 : 596-601
5. Ananth J, Venkatesh R, Burgoyne K et al. Atypical antipsychotic induced weight gain: pathophysiology and management. Ann Clin Psychiatry 2004 ; 16 : 75-85
6. Aquila R, Emanuel M. Weight gain and antipsychotic medications. J Clin Psychiatry 1999 ; 60 : 336-337
7. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999 ; 100 : 3-16 (Pubitemid 29309192)
8. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 2002 ; 47 : 742-749
9. Baptista T, Davila A, El Fakih Y et al. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol 2007 ; 22 : 205-211
10. Baptista T, Kin NM, Beaulieu S et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002 ; 35 : 205-219
11. Beaufrere B, Morio B. Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 2000 ; 54 (Suppl. 3) : S48-S53
12. Bromel T, Blum WF, Ziegler A et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998 ; 3 : 76-80
13. Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005 ; 20 : 105-112
14. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004 ; 65 (Suppl. 18) : 27-35
15. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006 ; 444 : 881-887
16. Ebenbichler CF, Laimer M, Eder U et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003 ; 64 : 1436-1439
17. Ebenbichler C, Laimer M, Kranebitter M et al. The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophr Res 2005 ; 75 : 143-146
18. Eder U, Mangweth B, Ebenbichler C et al. Association of olanzapineinduced weight gain with an increase in body fat. Am J Psychiatry 2001 ; 158 : 1719-1722
19. Engl J, Hanusch-Enserer U, Prager R et al. The metabolic syndrome: effects of a pronounced weight loss induced by bariatric surgery. Wien Klin Wochenschr 2005 ; 117 : 243-254
20. Engl J, Laimer M, Niederwanger A et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005 ; 10 : 1089-1096
21. Eriksson J, Franssila-Kallunki A, Ekstrand A et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989 ; 321 : 337-343
22. Facchini FS, Hollenbeck CB, Jeppesen J et al. Insulin resistance and cigarette smoking. Lancet 1992 ; 339 : 1128-1130
23. Haslam DW, James WPT. Obesity. Lancet 2005 ; 366 : 1197-1209
24. Haupt DW, Luber A, Maeda J et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005 ; 30 : 184-191
25. Henderson DC, Cagliero E, Copeland PM et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005 ; 62 : 19-28
26. Hofer A, Kemmler G, Eder U et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004 ; 65 : 932-939
27. Hofer A, Rettenbacher MA, Edlinger M et al. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry 2007 ; 40 : 1-8
28. Hummer M, Kemmler G, Kurz M et al. Weight gain induced by clozapine . Eur Neuropsychopharmacol 1995 ; 5 : 437-440
29. Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003 ; 52 : 2461-2474
30. Koro CE, Fedder DO, L ' Italien GJ et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002 ; 59 : 1021-1026
31. Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999 ; 156 : 312-314
32. Laimer M, Ebenbichler CF, Kranebitter M et al. Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors. J Clin Psychopharmacol 2005 ; 25 : 183-185
33. Larsson H, Elmstahl S, Ahren B. Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women. Diabetes 1996 ; 45 : 1580-1584
34. Lieberman JA, Stroup TS, MacEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 ; 353 : 1209-1223
35. Manson JE, Willett WC, Stampfer MJ et al. Body weight and mortality among women. N Engl J Med 1995 ; 333 : 677-685
36. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 ; 28 : 412-419
37. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004 ; 14 : 115-119
38. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004 ; 64 : 701-723
39. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003 ; 170 : 157-166
40. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology (Berl) 2001 ; 154 : 205-212
41. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000 ; 61 : 742-749
42. Melkersson K, Khan A, Hilding A et al. Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol 2001 ; 11 : 327-332
43. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001 ; 21 : 369-374
44. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007 ; 68 (Suppl. 1) : 20-27
45. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005 ; 19 (Suppl. 1) : 1-93
46. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007 ; 120 : S12 - 18
47. Rettenbacher MA, Ebenbichler C, Hofer A et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol 2006 ; 21 : 369-372
48. Sinha MK, Opentanova I, Ohannesian JP et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 1996 ; 98 : 1277-1282
49. Sowell MO, Mukhopadhyay N, Cavazzoni P et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002 ; 87 : 2918-2923
50. Stevens J, Cai J, Pamuk ER et al. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998 ; 338 : 1-7 (Pubitemid 28040168)
51. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005 ; 79 : 145-155
52. Gaal LF Van. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol 2006 ; 16 (Suppl. 3) : S142-S148
53. Gaal LF Van, Mertens IL, Block CE De. Mechanisms linking obesity with cardiovascular disease. Nature 2006 ; 444 : 875-880
54. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001 ; 24 : 59-73
55. Wirshing DA, Wirshing WC, Kysar L et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999 ; 60 : 358-363
56. Wu RR, Zhao JP, Liu ZN et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006 ; 186 : 572-578
57. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994 ; 372 : 425-432
58. Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology - from West to the rest. Diabetes Care 1992 ; 15 : 232-252